Hiroshi Onoda

1.3k total citations
19 papers, 1.0k citations indexed

About

Hiroshi Onoda is a scholar working on Hepatology, Oncology and Cancer Research. According to data from OpenAlex, Hiroshi Onoda has authored 19 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hepatology, 9 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Hiroshi Onoda's work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Cancer, Lipids, and Metabolism (8 papers) and Inflammatory Biomarkers in Disease Prognosis (7 papers). Hiroshi Onoda is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Cancer, Lipids, and Metabolism (8 papers) and Inflammatory Biomarkers in Disease Prognosis (7 papers). Hiroshi Onoda collaborates with scholars based in Japan and United States. Hiroshi Onoda's co-authors include Akiyoshi Kinoshita, Nami Imai, Nao Fushiya, Akira Iwaku, Kazuhiko Koike, Mutumi Oishi, Hirokazu Nishino, Hisao Tajiri, Masato Matsushima and Ken Tanaka and has published in prestigious journals such as British Journal of Cancer, Annals of Surgical Oncology and BMC Cancer.

In The Last Decade

Hiroshi Onoda

18 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroshi Onoda Japan 11 671 286 269 243 226 19 1.0k
Akiyoshi Kinoshita Japan 15 739 1.1× 322 1.1× 364 1.4× 387 1.6× 333 1.5× 43 1.2k
Mesut Şeker Türkiye 17 615 0.9× 174 0.6× 410 1.5× 71 0.3× 147 0.7× 98 1.3k
J E M Crozier United Kingdom 12 877 1.3× 273 1.0× 375 1.4× 64 0.3× 111 0.5× 14 1.2k
Nao Fushiya Japan 8 628 0.9× 275 1.0× 260 1.0× 234 1.0× 214 0.9× 15 874
B van Ooijen Netherlands 18 528 0.8× 347 1.2× 326 1.2× 111 0.5× 71 0.3× 27 1.1k
Akira Iwaku Japan 8 620 0.9× 251 0.9× 274 1.0× 213 0.9× 204 0.9× 16 866
Gudrun Absenger Austria 19 1.4k 2.1× 481 1.7× 401 1.5× 89 0.4× 135 0.6× 49 1.7k
Mutumi Oishi Japan 7 579 0.9× 244 0.9× 222 0.8× 204 0.8× 191 0.8× 7 781
Takeshi Aramaki Japan 21 519 0.8× 124 0.4× 608 2.3× 783 3.2× 298 1.3× 114 1.5k
Yoshimi Iwasaki Japan 15 592 0.9× 248 0.9× 373 1.4× 84 0.3× 69 0.3× 48 999

Countries citing papers authored by Hiroshi Onoda

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Onoda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Onoda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Onoda more than expected).

Fields of papers citing papers by Hiroshi Onoda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Onoda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Onoda. The network helps show where Hiroshi Onoda may publish in the future.

Co-authorship network of co-authors of Hiroshi Onoda

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Onoda. A scholar is included among the top collaborators of Hiroshi Onoda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Onoda. Hiroshi Onoda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Kinoshita, Akiyoshi, Hiroshi Onoda, Kaoru Ueda, et al.. (2015). Clinical characteristics and survival outcomes of super‐elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatology Research. 46(3). 6 indexed citations
2.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, Hirokazu Nishino, & Hisao Tajiri. (2015). C-Reactive Protein as a Prognostic Marker in Patients with Hepatocellular Carcinoma.. PubMed. 62(140). 966–70. 35 indexed citations
3.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2014). The Addition of C-Reactive Protein to Validated Staging Systems Improves Their Prognostic Ability in Patients with Hepatocellular Carcinoma. Oncology. 86(5-6). 308–317. 13 indexed citations
4.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2014). The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology. 22(3). 803–810. 364 indexed citations
5.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2013). Elevated Plasma Fibrinogen Levels Are Associated with a Poor Prognosis in Patients with Hepatocellular Carcinoma. Oncology. 85(5). 269–277. 50 indexed citations
6.
Iwaku, Akira, Akiyoshi Kinoshita, Hiroshi Onoda, et al.. (2013). The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection. Medical Oncology. 31(1). 787–787. 19 indexed citations
7.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2013). The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 13(1). 92 indexed citations
8.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2012). Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. British Journal of Cancer. 107(6). 988–993. 246 indexed citations
9.
Kinoshita, Akiyoshi, Hiroshi Onoda, Keiko Takano, et al.. (2012). Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Medical Oncology. 29(4). 2800–2808. 55 indexed citations
10.
Imai, Nami, Akiyoshi Kinoshita, Hiroshi Onoda, et al.. (2012). Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clinical & Translational Oncology. 15(7). 575–581. 7 indexed citations
11.
12.
Chihara, Dai, Yasuhiro Oki, Hiroshi Onoda, et al.. (2011). High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. International Journal of Hematology. 93(4). 502–508. 74 indexed citations
13.
Chihara, Dai, Yasuhiro Oki, Keitaro Matsuo, et al.. (2011). Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leukemia & lymphoma. 52(12). 2270–2275. 26 indexed citations
14.
Chihara, Dai, Yasuhiro Oki, Harumi Kato, et al.. (2010). Primary gastric diffuse large B‐cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG‐PET scan. European Journal Of Haematology. 84(6). 493–498. 18 indexed citations
15.
Onoda, Hiroshi, et al.. (2004). The relationship between the intracellular redox status of immune cells and progression of hepatitis C virus related chronic liver disease. Japanese Journal of Clinical Immunology. 27(5). 315–321. 1 indexed citations
16.
Kawabe, Takashi, et al.. (2000). [Two cases of transcatheter therapy to hepatocellular carcinoma supplied by the right internal mammary artery].. PubMed. 97(5). 585–9. 2 indexed citations
17.
Otsubo, O, Hiroaki Nozaki, Ikuo Takahashi, et al.. (1997). Relationship between macrophage infiltration of renal allografts and chronic renal impairment. Transplantation Proceedings. 29(7). 2783–2786. 6 indexed citations
18.
Katsuura, Tetsuo, et al.. (1989). Effect of head cooling on man at rest and during exercise under heat stress.. The Annals of physiological anthropology. 8(1). 49–50. 7 indexed citations
19.
Yagi, Masao, Hiroshi Onoda, Taku Watanabe, et al.. (1988). [Clinical significance of PFD test and fecal chymotrypsin test in postoperative pancreatic exocrine insufficiency].. PubMed. 85(6). 1282–7. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Akiyoshi Kinoshita Breakdown of academic impact, for papers by Mesut Şeker Breakdown of academic impact, for papers by J E M Crozier Breakdown of academic impact, for papers by Nao Fushiya Breakdown of academic impact, for papers by B van Ooijen Breakdown of academic impact, for papers by Akira Iwaku Breakdown of academic impact, for papers by Gudrun Absenger Breakdown of academic impact, for papers by Mutumi Oishi Breakdown of academic impact, for papers by Takeshi Aramaki Breakdown of academic impact, for papers by Yoshimi Iwasaki
Rankless by CCL
2026